Table 1.
Baseline Characteristics of the Study Population
| Baseline Characteristic | All Patients, n = 1419 | Patients With a Genotypic Resistance Test, n = 646 | No Minor InSTI Mutation, n = 542 | ≥1 Minor InSTI Mutation, n = 104 |
|---|---|---|---|---|
| Median (IQR) age at start of combined antiretroviral treatment, years | 39 (31–49) | 38 (30–49) | 38 (30–49) | 37 (31–47.5) |
| Sex (%) | ||||
| Male | 1176 (82.9) | 539 (83.4) | 457 (84.3) | 82 (78.9) |
| Female | 243 (17.1) | 107 (16.6) | 85 (15.7) | 22 (21.2) |
| Ethnicity (%) | ||||
| White | 1096 (77.2) | 508 (78.6) | 425 (78.4) | 83 (79.8) |
| Black | 168 (11.8) | 63 (9.8) | 47 (8.7) | 16 (15.4) |
| Other | 155 (10.9) | 75 (11.6) | 70 (12.9) | 5 (4.8) |
| Transmission category (%) | ||||
| Men who have sex with men | 842 (59.4) | 402 (62.2) | 335 (61.8) | 67 (64.4) |
| Heterosexual males | 241 (17.0) | 99 (15.3) | 89 (16.4) | 10 (9.6) |
| Heterosexual females | 195 (13.7) | 91 (14.1) | 71 (13.1) | 20 (19.2) |
| Intravenous drug users | 59 (4.2) | 22 (3.3) | 17 (3.1) | 4 (3.9) |
| Other | 82 (5.8)) | 33 (5.1) | 30 (5.5) | 3 (2.9) |
| Subtype (%) | ||||
| B | 364 (25.7) | 364 (56.4) | 312 (57.6) | 52 (50.0) |
| non-B | 253 (17.8) | 253 (39.2) | 204 (37.6) | 49 (47.1) |
| not available | 802 (56.5) | 29 (4.5) | 26 (4.8) | 4 (3.9) |
| HIV-1 RNA (%),copies/mL | ||||
| <10 000 | 437 (30.8) | 194 (30.0) | 161 (29.7) | 33 (31.7) |
| 10 000–99 999 | 604 (42.6) | 260 (40.3) | 218 (40.2) | 42 (40.4) |
| ≥100 000 | 378 (26.6) | 192 (29.7) | 163 (30.1) | 29 (27.9) |
| Log median (IQR) HIV-1 RNA copies/mL | 4.5 (3.5–5.1) | 4.5 (3.7–5.2) | 4.5 (3.7–5.2) | 4.5 (3.3–5.1) |
| CD4 cell count (%),cells/µL | ||||
| <200 | 281 (19.8) | 135 (20.9) | 106 (19.6) | 29 (27.9) |
| 200–500 | 724 (51.0) | 306 (47.4) | 267 (49.3) | 39 (37.5) |
| >500 | 414 (29.2) | 205 (31.7) | 169 (31.2) | 36 (34.6) |
| Median (IQR) CD4 cells/µL | 381 (226–549) | 391 (230–551) | 391 (238–552) | 386 (186–545) |
| AIDS-defining event at baseline (%) | 125 (8.8) | 43 (6.7) | 35 (6.5) | 8 (7.7) |
| InSTI administered (%) | ||||
| RGV | 213 (15.0) | 67 (10.4) | 54 (10.0) | 13 (12.5) |
| EVG | 281 (19.8) | 124 (19.2) | 108 (19.9) | 16 (15.4) |
| DTG | 925 (65.2) | 455 (70.4) | 380 (70.1) | 75 (72.1) |
| Antiretroviral treatment combinations (%) | ||||
| 3TC+ABC+DTG | 460 (32.4) | 227 (35.1) | 198 (36.5) | 29 (27.9) |
| DTG+ETC+TDF | 259 (18.3) | 150 (23.2) | 120 (22.1) | 30 (28.9) |
| DTG+ETC+TAF | 143 (10.8) | 42 (6.5) | 34 (6.3) | 8 (7.7) |
| COB+ETC+EVG+TAF | 130 (9.2) | 53 (8.2) | 47 (8.7) | 6 (5.8) |
| COB+ETC+EVG+TDF | 123 (8.7) | 59 (9.1) | 50 (9.2) | 9 (8.7) |
| ETC+RGV+TDF | 126 (8.9) | 37 (5.7) | 30 (5.5) | 7 (6.7) |
| Other drug combinations | 178 (11.8) | 78 (12.1) | 63 (11.6) | 15 (14.4) |
Abbreviations: 3TC, lamivudine; ABC, abacavir; COB, cobicistat; DTG, dolutegravir; ETC, emtricitabine; EVG, elvitegravir; HIV, human immunodeficiency virus; InSTI, integrase strand transfer inhibitor; IQR, interquartile range; RGV, raltegravir; TAF, tenofovir alafenamide; TDF, tenofovir.